Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00591149 · ClinicalTrials.gov registry record · Phase 2
Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer
A Phase 2 study, sponsored by University of Kansas Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT00591149 is a Phase 2 study that was terminated before completion, run by University of Kansas Medical Center. The registered enrollment target is 16 participants.
The verdict
NCT00591149, a Phase 2 study, was terminated before completion, sponsored by University of Kansas Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
A study of Oxaliplatin and Docetaxel followed by Cetuximab for head and neck cancer patients to determine their effect on the control and reduction of tumor size
Interventions
- DRUG Docetaxel
- DRUG Oxaliplatin
- DRUG Cetuximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2007-06 |
| Est. Completion | 2012-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00591149
The ClinicalTrials.gov registry entry for NCT00591149 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Docetaxel is the first listed.
NCT00591149 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00591149 about?
NCT00591149 is a clinical study titled "Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer". A study of Oxaliplatin and Docetaxel followed by Cetuximab for head and neck cancer patients to determine their effect on the control and reduction of tumor size
What is the current status of trial NCT00591149?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2007-06. Estimated completion is 2012-04.
What interventions are being tested in trial NCT00591149?
The interventions under investigation include: Docetaxel (DRUG), Oxaliplatin (DRUG), Cetuximab (DRUG).
Who is sponsoring clinical trial NCT00591149?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.